Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

JANX

Janux Therapeutics Inc

Apr 18 • 04:00PM ET

48.85

Dollar change +0.89
Percentage change 1.86	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB IWN VTWO VHT IWC ITOT AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.34	Insider Own	33.35%	Shs Outstand	46.25M	Perf Week	-2.30%
Market Cap	2.52B	Forward P/E	-	EPS next Y	-1.64	Insider Trans	17.37%	Shs Float	34.43M	Perf Month	26.46%
Income	-58.29M	PEG	-	EPS next Q	-0.33	Inst Own	57.77%	Short Float	10.90%	Perf Quarter	429.83%
Sales	8.08M	P/S	312.33	EPS this Y	-13.64%	Inst Trans	1.30%	Short Ratio	4.28	Perf Half Y	523.09%
Book/sh	7.44	P/B	6.56	EPS next Y	-9.25%	ROA	-15.66%	Short Interest	3.75M	Perf Year	218.03%
Cash/sh	6.66	P/C	7.34	EPS next 5Y	-	ROE	-17.53%	52W Range	5.65 - 58.69	Perf YTD	355.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-92.62%	ROI	-15.87%	52W High	-16.77%	Beta	3.98
Dividend TTM	-	Quick Ratio	26.80	Sales past 5Y	32.66%	Gross Margin	75.81%	52W Low	764.60%	ATR (14)	3.96
Dividend Ex-Date	-	Current Ratio	26.80	EPS Y/Y TTM	11.77%	Oper. Margin	-902.87%	RSI (14)	66.53	Volatility	7.14% 8.39%
Employees	64	Debt/Eq	0.07	Sales Y/Y TTM	-6.14%	Profit Margin	-721.18%	Recom	1.00	Target Price	58.50
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	34.79%	Payout	-	Rel Volume	0.45	Prev Close	47.96
Sales Surprise	228.13%	EPS Surprise	39.79%	Sales Q/Q	-13.50%	Earnings	Mar 08 AMC	Avg Volume	876.32K	Price	48.85
SMA20	17.97%	SMA50	47.89%	SMA200	209.52%	Trades		Volume	396,699	Change	1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-21-24	Initiated	BTIG Research	Buy	$62
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight	$100
Apr-06-23	Initiated	Wedbush	Outperform	$24
Nov-14-22	Initiated	William Blair	Outperform

Apr-15-24 12:54PM	Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors (Zacks)
Apr-12-24 08:50AM	Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +5.30%
05:40AM	Why Janux Therapeutics Stock Is Crushing It This Week (Motley Fool)
Apr-11-24 04:19PM	Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily) +12.06%
02:13PM	Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday? (Benzinga)
09:55AM	Loading…
09:55AM	Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet (Zacks)
09:17AM	Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
Apr-10-24 06:39PM	Why Janux Therapeutics Stock Soared as the Market Sagged Today (Motley Fool) +11.47%
Apr-08-24 09:35AM	After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX) (Zacks) +9.99%
Mar-28-24 12:00PM	Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-22-24 09:55AM	Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade (Zacks)
Mar-20-24 03:44PM	Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst (Benzinga)
Mar-15-24 10:53AM	JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
09:45AM	2 Stocks That Have More Than Tripled This Year: Are They Buys? (Motley Fool)
Mar-08-24 04:31PM	Janux Therapeutics Inc (JANX) Reports Encouraging Clinical Data and Solid Financial Position ... (GuruFocus.com)
04:01PM	Loading…
04:01PM	Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-02-24 06:56AM	After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy? (Motley Fool)
Mar-01-24 08:50AM	Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why (Zacks)
Feb-29-24 01:22AM	Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Feb-27-24 05:00PM	Janux Therapeutics Announces Proposed Public Offering of Common Stock (Business Wire) +229.47%
04:04PM	Janux Stock Launches 230% On Its 'Significant Opportunity' In Prostate Cancer Treatment (Investor's Business Daily)
10:07AM	Janux Therapeutics Nearly Triples As Prostate Cancer Drug Shows 'Significant Opportunity' (Investor's Business Daily)
07:46AM	Why Is Janux Therapeutics (JANX) Stock Up 108% Today? (InvestorPlace)
07:15AM	Janux shares triple on early cancer immunotherapy data (BioPharma Dive)
Feb-26-24 04:05PM	Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors (Business Wire)
Feb-21-24 02:39AM	Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last? (Zacks) +31.93%
Feb-20-24 08:00AM	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 (Business Wire) +5.62%
Jan-08-24 09:00AM	Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer (Business Wire)
Dec-01-23 09:55AM	Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect? (Zacks)
Nov-15-23 09:55AM	Wall Street Analysts See a 220.17% Upside in Janux Therapeutics, Inc. (JANX): Can the Stock Really Move This High? (Zacks) +5.40%
09:35AM	Loading…
Nov-10-23 09:35AM	Janux Therapeutics, Inc. (JANX) Loses -34.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-07-23 04:01PM	Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-10-23 09:55AM	Wall Street Analysts Think Janux Therapeutics, Inc. (JANX) Could Surge 120.82%: Read This Before Placing a Bet (Zacks)
Aug-08-23 05:40PM	Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire)
Jul-20-23 12:00PM	All You Need to Know About Janux Therapeutics, Inc. (JANX) Rating Upgrade to Buy (Zacks)
09:55AM	Wall Street Analysts Believe Janux Therapeutics, Inc. (JANX) Could Rally 120.65%: Here's is How to Trade (Zacks)
06:40AM	Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Could Be 28% Below Their Intrinsic Value Estimate (Simply Wall St.)
Jul-17-23 08:45AM	Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire)
08:00AM	Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs (Business Wire)
Jun-05-23 04:35PM	Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development (Business Wire)
10:38AM	Shareholders have faith in loss-making Janux Therapeutics (NASDAQ:JANX) as stock climbs 20% in past week, taking one-year gain to 29% (Simply Wall St.)
May-09-23 05:15PM	Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-02-23 10:01AM	Analysts Estimate Janux Therapeutics, Inc. (JANX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-24-23 04:01PM	Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences (Business Wire)
Apr-20-23 04:01PM	Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors (Business Wire)
Apr-05-23 10:22AM	Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace) -6.34%
Mar-10-23 04:01PM	Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Feb-14-23 12:00PM	Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference (Business Wire) -8.62%
Feb-10-23 05:30AM	Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Could Be 22% Above Their Intrinsic Value Estimate (Simply Wall St.)
Jan-10-23 12:00PM	Janux Therapeutics, Inc. (JANX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +5.75%
Dec-27-22 09:00AM	Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors (Business Wire)
08:51AM	Janux Therapeutics (NASDAQ:JANX) investors are sitting on a loss of 44% if they invested a year ago (Simply Wall St.)
Nov-23-22 09:55AM	Here's Why Janux Therapeutics, Inc. (JANX) Looks Ripe for Bottom Fishing (Zacks)
Nov-22-22 06:00AM	Janux Therapeutics to Present at Upcoming Investor Conferences in November (Business Wire)
Nov-21-22 12:22PM	7 Short-Squeeze Stocks for Bold Contrarians to Consider (InvestorPlace)
Nov-16-22 06:15AM	Janux Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 04:01PM	Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) +8.31%
Oct-27-22 09:18AM	Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth (Simply Wall St.)
Oct-22-22 10:01AM	Why Janux Therapeutics Shares Rose 33.1% This Week (Motley Fool)
Oct-12-22 09:00AM	Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer (Business Wire) +5.79%
07:58AM	7 Short-Squeeze Stocks to Buy for Contrarian Investors (InvestorPlace)
Sep-23-22 06:00AM	Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources (Business Wire) -6.08%
Sep-22-22 06:00AM	Janux Therapeutics Appoints Winston Kung to Board of Directors (Business Wire)
Aug-31-22 09:00AM	Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September (Business Wire)
Aug-09-22 04:01PM	Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (Business Wire) -9.71%
Jul-04-22 08:43AM	Further weakness as Janux Therapeutics (NASDAQ:JANX) drops 9.3% this week, taking one-year losses to 54% (Simply Wall St.)
Jun-02-22 08:00AM	Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference (Business Wire) +7.25%
May-31-22 08:00AM	Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer (Business Wire) -5.03%
May-20-22 07:37AM	Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business (Simply Wall St.)
May-10-22 04:01PM	Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (Business Wire) +5.04%
Apr-26-22 08:30AM	Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr (Business Wire)
Mar-18-22 04:01PM	Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire)
Mar-01-22 08:01AM	Janux Therapeutics to Present at Upcoming March Investor Conferences (Business Wire)
08:00AM	Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer (Business Wire)
Jan-05-22 04:01PM	Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference (Business Wire)
Dec-11-21 08:44AM	We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth (Simply Wall St.)
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital (Insider Monkey)
Nov-09-21 04:01PM	Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results (Business Wire) -6.88%
Nov-08-21 08:00AM	Janux Therapeutics to Present Virtually at Upcoming Investor Conferences (Business Wire) -11.09%
Sep-12-21 10:40AM	Insiders at Janux Therapeutics, Inc. (NASDAQ:JANX) snagged a bargain: a US$631k profit on a US$1m buy (Simply Wall St.)
Sep-09-21 04:01PM	Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors (Business Wire) +7.16%
Sep-07-21 04:01PM	Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference (Business Wire) -5.43%
Jul-19-21 08:00AM	Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer (Business Wire)
Jun-15-21 04:01PM	Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire) -7.84%

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Avalon Ventures XI, L.P.	10% Owner	Nov 13 '23	Buy	5.87	849,854	4,988,643	849,854	Nov 13 07:11 PM
Reardon Tighe	Acting Chief Financial Officer	Nov 13 '23	Buy	5.87	849,854	4,988,643	849,854	Nov 15 04:48 PM
Lichter Jay	Director	Nov 13 '23	Buy	5.87	849,854	4,988,643	849,854	Nov 15 04:46 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 19 '23	Buy	12.46	495,008	6,167,800	8,117,246	Jul 21 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JANX

Janux Therapeutics Inc

Upgrade your FINVIZ experience